Our findings suggest that long-term treatment with EGX358 prevents senktide-induced vasodilation and enhances spatial and object recognition memory to similar extents as the potent estrogen 17β-estradiol (E2) and commercially available ERβ agonist DPN, but does not affect anxiety-or depression-like behaviors or body weight. Here, ESR2 is linked to major depressive disorder.